MannKind Corporation (MNKD): Price and Financial Metrics
Today's Latest Price: $1.78 USD
Jul 10 4:00pm Add MNKD to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank MNKD Stock Summary The capital turnover (annual revenue relative to shareholder's equity) for MNKD is -0.31 -- better than merely 6.98% of US stocks. Equity multiplier, or assets relative to shareholders' equity, comes in at -0.46 for Mannkind Corp; that's greater than it is for merely 6.34% of US stocks. As for revenue growth, note that MNKD's revenue has grown 47.76% over the past 12 months; that beats the revenue growth of 89.25% of US companies in our set. Stocks that are quantitatively similar to MNKD, based on their financial statements, market capitalization, and price volatility, are NR, ADMS, OPTN, ESTA, and ACRX. Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to www.mannkindcorp.com. MNKD Price/Volume Stats
379.39M MannKind Corporation (MNKD) Company Bio
MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.
MNKD Latest News Stream
All News Types Commentary Corp. News Debt Offering Downgrade Earnings Hedge Fund M&A Mgmt Change New Coverage (Bullish) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering
Event/Time News Detail Loading, please wait... Latest MNKD News From Around the Web
Below are the latest news stories about Mannkind Corp that investors may wish to consider to help them evaluate MNKD as an investment opportunity.
The following slide deck was published by MannKind Corporation in conjunction with this event....
MannKind Corporation (MNKD) Lytham Partners Virtual Investor Growth Conference June 24, 2020 12:00 PM ET Company Participants Michael Castagna - CEO Conference Call Participants Robert Blum - Lytham Partners Presentation Robert Blum All right. Hello and thank you all for joining us today during the June 2020 Lytham Partners Virtual...
Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks.
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
Read More 'MNKD' Stories Here
MNKD Price Returns
-72.22% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7653 seconds.